Method for treating or preventing parkinson's disease using heterocyclic GLP-1 receptor agonists
Oral GLP-1 receptor agonists address the limitations of current Parkinson's disease treatments by enhancing dopaminergic neuron density and improving motor deficits, offering a potential neuroprotective treatment for the disease.
Patent Information
- Application Number
- PCT/US2026/028290
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current therapeutic strategies for Parkinson's disease primarily focus on alleviating symptoms but fail to halt or reverse the underlying neurodegenerative process, and long-term use of levodopa is associated with motor complications.
Oral administration of specific GLP-1 receptor agonists, such as compounds of Formula I or their pharmaceutically acceptable salts, to treat or prevent Parkinson's disease by promoting neuroprotection and increasing dopaminergic neuron density.
The GLP-1 receptor agonists enhance dopaminergic neuron density and improve motor deficits in Parkinson's disease models, as evidenced by improved performance in behavioral tests and histopathological assessments.
Smart Images

Figure US2026028290_19112026_PF_FP_ABST
Abstract
Description
METHOD FOR TREATING OR PREVENTING PARKINSON’S DISEASE USING HETEROCYCLIC GLP-1 RECEPTOR AGONISTSCROSS REFERENCE TO RELATED APPLICATIONS
[0001] The application claims the benefit of International Patent Application Number PCT / CN2025 / 095145, filed on May 15, 2025, which is hereby incorporated herein by reference in its entirety.FIELD
[0002] This disclosure relates to methods for treating or preventing Parkinson’s disease using GLP-1 receptor agonists.BACKGROUND
[0003] Incretin metabolic hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are important in the regulation of glucose homeostasis. Medicaments targeting this family of intestinal peptides, such as GLP-1 receptor agonists, have been shown to suppress glucagon production, decrease gastric motility, and increase satiety.
[0004] Parkinson’s disease (PD) ranks among the most prevalent neurodegenerative disorders globally. The pathology of PD is characterized by the progressive loss of dopaminergic neurons (DA) in the substantia nigra (SN) and the degeneration of nerve fibers which project to the striatum. Current therapeutic strategies for PD are primarily focused on alleviating symptoms in affected individuals, yet they lack the capacity to halt or reverse the underlying neurodegenerative process. A central objective of these treatments is the restoration of dopamine levels, as depletion of this neurotransmitter is a key pathological hallmark driving PD’s motor symptoms. However, long-term use of levodopa (L-dopa)-the gold-standard therapy for managing PD — is frequently associated with the development of motor complications, including fluctuations in symptom control (motor fluctuations) and involuntary movements (dyskinesias). Over time, these issues lead to significant disability in a substantial proportion of PD patients.
[0005] Recent evidence has highlighted shared pathological mechanisms between neurodegenerative conditions like PD and metabolic disorders such as type 2 diabetes mellitus (T2DM), particularly emphasizing the role of interactions within the gut-brain axis. Some investigations show that GLP-1 receptor (GLP-1 R) agonists have neuroprotective effects in animal models of PD. The GLP-1 mimetic peptide exendin-4 (Exenatide) approved to treat Type 2 diabetes showed beneficial effects in preclinical PD models. Further investigation on small molecule GLP-1R agonists is still needed.SUMMARY
[0006] Provided herein is a method for treating or preventing Parkinson’s Disease (PD) in a subject, comprising orally administrating an effective amount of glucagon-like peptide- 1 (GLP-1) receptor agonist to the subject, wherein the GLP-1 receptor agonist is selected from a compound of Formula I:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, wherein:Q2is N or CRQA;RQBis -S(O)(NRa)Rbor -P(O)Ra’Rb’;Rais hydrogen, cyano, C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of halo, oxo, C1-6 alkoxy, C3-6 cycloalkyl, and heteroaryl, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or C6-10 aryl optionally substituted with 1-3 independently selected C1-3 alkyl;Rbis C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or C6-10 aryl optionally substituted with 1-3 independently selected C1-3 alkyl;or Ra and Rb taken together with the atoms to which each is attached form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-3 independently selected C1-6 alkyl;Ra’ and Rb’ are independently selected from the group consisting of C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and C6-10 aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; orRa’ and Rb’ taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra’ and Rb’) are heteroatoms each independently selected from the group consisting of: 0, S, and N. wherein the ring is optionally substituted with from 1-3 independently selected C1-6 alkyl:each RQA is independently hydrogen, halo, cyano, hydroxy, -NRcRd, -C(O)NRcRd, -S(O)0-2Re, C1-6 alkyl optionally substituted with 1-6 independently selected Rf, C1-6 alkoxy optionally substituted with 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy, 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and -C(O)(C1-6 alkyl), C6-10 aryl optionally substituted with 1-3 independently selected -C(O)(C1-6 alkyl), and 5-10 membered heteroaryl optionally substituted with 1-6 independently selected Rg;or Raor Rband an adjacent RQAare taken together with the atom to which each is attached to form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-2 independently selected Rh;q is O, 1, 2, 3, 4, or 5;each RA is independently halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-6 cycloalkyl;R3 is hydrogen or C1-6 alkyl optionally substituted with 1-6 substituents independently selected from the group consisting of halo, hydroxy, and C1-6 alkoxy;R9is -C(O)OR9a, -C(O)NR9aR9b, 5-6 membered heteroaryl optionally substituted with 1 -3 independently selected R9c, 4-6 membered heterocyclyl optionally substituted with 1-3 independentlyX1is O or S;R9ais hydrogen or Ci-6 alkyl;R9bis hydrogen, Ci-e alkyl, -C(O)(Ci-6 alkyl), -S(0)o-2(Ci-6 alkyl), or cyano;each R9c is independently hydrogen, oxo, C1-6 alkyl optionally substituted with 1-6 independently selected halo and C1-6 alkoxy, or -C(O)(C1-6 alkyl);v is 0, 1, 2, or 3;each RCa is independently halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or NRcRd; or a pair of RCaon the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including 3-8 ring atoms;each Rc and Rd are each independently hydrogen, C1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(C3-6 cycloalkyl), -C(O)O(C1-6 alkyl), -S(O)1-2(C1-6 alkyl), or -S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(C3-6 cycloalkyl), -C(O)O(C1-6 alkyl), -S(O)1-2(C1-6 alkyl), and -S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with 1-6 substituents independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy;each Re is independently hydrogen, C1-6 alkyl, or C1-6 haloalkyl;w is 0, 1, 2, or 3;each R1f is independently C1-6 alkyl, wherein each C1-6 alkyl is independently optionally substituted with 1-6 independently selected Rf;each Rf is independently halo, hydroxy, -NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, or 3-12 membered heterocyclyl which is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxy, C1-6 alkyl, and 3-12 membered heterocyclyl;each Rg is independently C1-6 alkyl, C1-6 alkoxy, -NRcRd, or 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and -C(O)C1-6 alkyl; andeach Rh is independently halo, cyano, hydroxy, C1-6 alkyl, C1-6 haloalkyl, -NH2, -NH(C1-3 alkyl), -N(C1-3 alkyl)2, C1-3 alkoxy, or C1-3 haloalkoxy.
[0007] In some embodiments, provided herein is a method for treating or preventing Parkinson’s Disease (PD) in a subject, comprising orally administrating an effective amount of glucagon-like peptide -1 (GLP-1) receptor agonist to the subject, wherein the GLP-1 receptor agonist is selected from Table 1 or Table 2, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0008] In some embodiments, tire GLP-1 receptor agonists described herein, such as a compound of Formula I, Formula la, Formula II, Formula Ila, Formula III, or a compound selected from Table 1 or 2, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, have a benefit on neuroprotection in Parkinson’s disease.
[0009] In some embodiments, the GLP-1 receptor agonists described herein, such as a compound of Formula I, Formula la, Formula II, Formula Ila, Formula III, or a compound selected from Table 1 or 2, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, increase the density of dopaminergic neurons in the brain and subsequently improve the recovery on the autonomous activity or motor deficit, which can be evaluated in the activity behavior tests such as pole test, rotarod test and open field.
[0010] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to tire same extent as if each individual publication, patent, or patentapplication was specifically and individually indicated to be incorporated by reference. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, tire specification is intended to supersede and / or take precedence over any such contradictory material.BRIEF DESCRIPTION OF THE DRAWINGS
[0011] FIG. 1 illustrates a dosing regimen of the GLP-1R agonists, respectively.
[0012] FIG.2 shows the climbing duration in the pole test 7 days post the MPTP induction in hGLP-1R mice treated with the GLP-1R agonists, respectively. **P<0.01, compared to the MPTP model group by one-way ANOVA Dunnett post hoc and ####P<0.0001, MPTP model group compared to normal control group by Mann- Whitney test.
[0013] FIG.3 shows the latency to fall in the rotarod test 7 days post the MPTP induction in hGLP-1R mice treated with the GLP-1R agonists, respectively. *P<0.05, ****P<0.0001. compared to the MPTP model group by one-way ANOVA Dunnett post hoc and ####P<0.0001. MPTP model group compared to normal control group by Mann-Whitney test.
[0014] FIG.4A-4E show the parameters in the open field test 7 days post the MPTP induction in hGLP-1R mice treated with the GLP-1R agonists, respectively. ## pcO. Ol, ### pcO. OOl, ####p<( ).()()() I vs normal control by Mann- Whitney test, *p<0.05, **p<0.01, ****p<0.0001 vs MPTP model group by oneway ANOVA test.
[0015] FIG.5A-5B show the histopathology of dopaminergic neurons characterized by tyrosine hydroxylase (TH) expression in the substantial nigra (SN) region of die MPTP induced PD-like mice brain. ## pcO. Ol vs normal control by Unpaired T-test, Mann-Whitney test, **p<0.01 vs MPTP model group by one-way ANOVA test.
[0016] FIG.6A-6E show the weight loss effect of the GLP-1R agonists in the MPTP induced PD-like mice (FIG.6A-6C), Data were presented as Mean ± Sem; Two way ANOVA followed by Dunnett test by Prism GraphPad; n = 6-12, *P<0.05, ****P<0.0001 compared to tire MPTP model group; and food intake effect of the GLP-1R agonists in the MPTP induced PD-like mice (FIG.6D-6E). Data were presented as Mean ± Sem; Two way ANOVA followed by Dunnett test by Prism GraphPad; n = 6-12, *P<0.05, **P<0.01, ****P<0.0001 compared to the MPTP model group.DETAILED DESCRIPTION
[0017] Before the present compounds and methods are described, it is to be understood that the disclosure is not limited to the methodologies, protocols, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe embodiments of the present disclosure and is in no way intended to limit the scope of tire present disclosure as set forth in the appended claims.Definitions
[0018] The following description sets forth exemplary embodiments of die present technology. It should be recognized, however, diat such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.
[0019] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
[0020] A dashthat is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -C(0)NH2is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line or a dashed line drawn through a line in a structure indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.
[0021] The prefix “Cu-v” indicates that the following group has from u to v carbon atoms. For example, “Ci-6 alkyl” indicates that the alkyl group has from 1 to 6 carbon atoms.
[0022] Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term “about” includes the indicated amount ± 10%. In other embodiments, the term “about” includes tire indicated amount ± 5%. In certain other embodiments, the term “about” includes the indicated amount ± 1%. Also, to the term “about X” includes description of “X”. Also, tire singular forms “a” and “the” include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to “the compound” includes a plurality of such compounds and reference to “the assay” includes reference to one or more assays and equivalents thereof known to those skilled in the art.
[0023] The term “substantially” as used herein is intended to mean greater than about 35%, or about 40%, or about 45%. or about 50%, or about 55%, or about 60%, or about 65%, or about 70%, or about 75%, or about 80%. or about 85%, or about 90%, or about 95%.
[0024] “Alkyl” refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C1.20 alkyl), 1 to 12 carbon atoms (i.e., C1.12 alkyl), 1 to 8 carbon atoms (i.e., C1-8 alkyl), 1 to 6 carbon atoms (i.e., Ci-e alkyl), or 1 to 4 carbon atoms (i.e., C1-4 alkyl). Examples of alkyl groups include, e.g., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl. 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, “butyl” includes n-butyl (i.e., -(QUhCEB), sec-butyl (i.e., -CH(CH2)CH2CH3), isobutyl (i.e.,-CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and “propyl” includes n-propyl (i.e., -(CH2)2CH3), and isopropyl (i.e., -CH(CH3)2).
[0025] “Alkenyl” refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e.,alkenyl), 2 to 12 carbon atoms (i.e.,alkenyl), 2 to 8 carbon atoms (i.e., C2-8 alkenyl), 2 to 6 carbon atoms (i.e., C2-6 alkenyl), or 2 to 4 carbon atoms (i.e., C2-4 alkenyl). Examples of alkenyl groups include, e.g., ethenyl, propenyl, butadienyl (including1,2-butadienyl, and 1,3-butadienyl).
[0026] “Alkynyl” refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e.,alkynyl), 2 to 12 carbon atoms (i.e.,alkynyl), 2 to 8 carbon atoms (i.e., C2-8 alkynyl), 2 to 6 carbon atoms (i.e., C2-6 alkynyl), or 2 to 4 carbon atoms (i.e., C2-4 alkynyl). The term “alkynyl” also includes those groups having one triple bond and one double bond.
[0027] Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent “alkyl” group, a divalent “aryl” group, etc., may also be referred to as an “alkylene” group or an “alkylenyl” group, an “arylene” group or an “arylenyl” group, respectively.
[0028] “Alkoxy” refers to tire group “alkyl-O-”. Examples of alkoxy groups include, e.g., methoxy, ethoxy, n-propoxy, iso-propoxy. n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy. and1.2-dimethylbutoxy.
[0029] “Alkoxyalkyl” refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by an alkoxy group as defined herein.
[0030] “Haloalkyl” refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to tire number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two (“di”) or three (“tri”) halo groups, which may be, but are not necessarily, tire same halogen. Examples of haloalkyl include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl,2.2.2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
[0031] “Haloalkoxy” refers to an alkoxy group as defined above, wherein one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by an independently selected halo group.
[0032] “Haloalkoxyalkyl” refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by a haloalkoxy group as defined herein.
[0033] “Hydroxyalkyl” refers to an alkyl group as defined above, wherein one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by hydroxy.
[0034] “Cyanoalkyl” refers to an alkyl group as defined above, wherein one, or one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by cyano.
[0035] “Alkylthio” refers to the group “alkyl-S-”.
[0036] “Acyl” refers to a group -C(O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cyclohexyl carbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
[0037] ‘ ‘Amido” refers to both a “C-amido” group which refers to the group -C(O)NRyRzand an “N-amido” group which refers to the group -NRyC(O)Rz, wherein Ryand Rzare independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein, or Ryand Rzare taken together to form a cycloalkyl or heterocyclyl; each of which may be optionally substituted, as defined herein.
[0038] ‘ ‘Amino” refers to the group -NRyRzwherein Ryand Rzare independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0039] ‘ ‘Amidino” refers to -C(NRy)(NRz2), wherein Ryand Rzare independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0040] “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C6-20 aryl), 6 to 12 carbon ring atoms (i.e., Ce-n aryl), or 6 to 10 carbon ring atoms (i.e., Ce-io aryl). Examples of aryl groups include, e.g., phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl regardless of point of attachment. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl regardless of point of attachment. If one or more aryl groups are fused with a cycloalkyl, the resulting ring system is cycloalkyl regardless of point of attachment.
[0041] “Carbamoyl” refers to both an “O-carbamoyl” group which refers to the group -O-C(O)NRyRzand an “N-carbamoyl” group which refers to the group -NRyC(O)ORz, wherein Ryand Rzare independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0042] “Carboxyl ester” or “ester” refer to both -OC(O)RXand -C(O)ORX, wherein Rxis alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0043] “Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., die cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp3carbon atom (i.e., at least one non-aromatic ring). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C3-20 cycloalkyl), 3 to 14 ring carbon atoms (i.e., C3-14 cycloalkyl), 3 to 12 ring carbon atoms (i.e., C3-12 cycloalkyl). 3 to 10 ring carbon atoms (i.e., C3-10 cycloalkyl), 3 to 8 ring carbon atoms (i.e., C3-8 cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C3-6 cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl. adamantyl, norbornyl, decalinyl, 7.7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Further, the term cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule. Still further, cycloalkyl also includes “spirocycloalkyl” when there are two positions for substitution on the same carbon atom, for example spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl.
[0044] “Cycloalkylalkyl” refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by a cycloalkyl group as defined herein.
[0045] ‘ ‘Imino” refers to a group -C(NRy)Rz, wherein Ryand Rzare each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0046] “Imido” refers to a group -C(O)NRyC(O)Rzor -N(C(O)Ry)C(O)Rz, wherein Ryand Rzare each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein, or Ryand Rzare taken together to form a heterocyclyl which may be optionally substituted, as defined herein.
[0047] “Halogen” or “halo” refers to atoms occupying group VIIA of the periodic table, such as fluoro, chloro, bromo, or iodo.
[0048] “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. The term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to. -NR-. -O-. -S-. -S(O)-, -S(O)2-, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted. Examples of heteroalkyl groups include -OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCHs, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkylinclude 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms, and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
[0049] “Heteroaryl” refers to an aromatic group having a single ring or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 ring carbon atoms (i.e., C1-20 heteroaryl), 3 to 12 ring carbon atoms (i.e., C3-12 heteroaryl), or 3 to 8 carbon ring atoms (i.e., C3-8 heteroaryl), and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In certain instances, heteroaryl includes 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, e.g., acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl, benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl. carbazolyl, cinnolinyl, dibenzofuranyl. dibenzothienyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl. 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl. phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl. pyrazinyl. pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl. quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, thienyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused-heteroaryl rings include, but are not limited to, benzo [d] thiazolyl, quinolinyl. isoquinolinyl, benzo[b]thienyl. indazolyl. benzo[d]imidazolyl, pyrazolo[l,5-a]pyridinyl. and imidazo[l,5-a]pyridinyl, where the heteroaryl can be bound via either ring of the fused system. Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.
[0050] “Heterocyclyl” refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes heterocycloalkenyl groups (i.e.. the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro, and may comprise one or more (e.g., 1 to 3) oxo (=0) or N-oxide (-0 j moieties. Any non-aromatic ring or fused ring system containing at least one heteroatom and one non-aromatic ring is considered a heterocyclyl, regardless of the attachment to the remainder of the molecule. For example, fused ring systems such as decahydroquinazolinyl, 1,2,3,4-tetrahydroquinazolinyl, and 5, 6,7,8-tetrahydroquinazolinyl are heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to a cycloalkyl, an aryl, or heteroaryl ring,regardless of the attachment to the remainder of the molecule. As used herein, heterocyclyl has 2 to 20 ring carbon atoms (i.e., C2-20 heterocyclyl), 2 to 12 ring carbon atoms (i.e., C2-12 heterocyclyl), 2 to 10 ring carbon atoms (i.e., C2-10 heterocyclyl), 2 to 8 ring carbon atoms (i.e., C2-8 heterocyclyl), 3 to 12 ring carbon atoms (i.e., C3-12 heterocyclyl), 3 to 8 ring carbon atoms (i.e., C3-8 heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C3-6 heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms. 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include, e.g.. azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl. benzopyranyl. benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl. dihydropyranyl. hydropyranyl. thienyl[1,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl. octahydroisoindolyl. 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl. oxiranyl, oxetanyl, phenothiazinyl. phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl. tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiomorpholinyl, thiamorpholinyl,1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term “heterocyclyl” also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom. Examples of the spiro-heterocyclyl rings include, e.g., bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-l-azaspiro[3.3]heptanyl. Examples of the fused-heterocyclyl rings include, but are not limited to, 1, 2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.
[0051] “Sulfonyl” refers to the group -S(O)2Ry, where Ryis hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of sulfonyl are methyl sulfonyl, ethyl sulfonyl, phenylsulfonyl, and toluenesulfonyl.
[0052] “Sulfinyl” refers to the group -S(O)Ry. where Ryis hydrogen, alkyl, alkenyl, alkynyl. cycloalkyl, heterocyclyl. aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.
[0053] The terms “optional” or “optionally” means that tire subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” refers to any one or more (e.g.. 1 to 5, or 1 to 3) hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.
[0054] As used herein, the term “compound,” is meant to include any or all stereoisomers, geometric isomers, tautomers, and isotopically enriched analogs (e.g., deuterated analogs) of the structures depicted.Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.
[0055] Some of the compounds exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, tire compounds are understood by one of ordinary skill in tire art to comprise both amide and imidic acid tautomers. Thus, tire amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.
[0056] Any compound or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. These forms of compounds may also be referred to as “isotopically enriched analogs.” Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as2H,3H,11C,13C,14C,13N,15N,150,170,18O,31P,32P,35S,18F,36C1,123I, and125I, respectively. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as3H and14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or singlephoton emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
[0057] The term “isotopically enriched analogs” includes “deuterated analogs” of compounds described herein in which one or more hydrogens is / are replaced by deuterium, such as a hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in die art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
[0058] Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements, and / or an improvement in therapeutic index. An18F,3H,nC labeled compound may be useful for PET or SPECT or other imaging studies.
[0059] Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations describedbelow by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.
[0060] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
[0061] ‘ ‘Deuterated alkyl” refers to an alkyl group an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by a deuterium atom.
[0062] “Deuterated hydroxyalkyl” refers to a hydroxyalkyl group as defined above, wherein one or more (e.g.. 1 to 6 or 1 to 3) hydrogen atoms are replaced by a deuterium atom.
[0063] ‘ ‘Deuterated cyclopropyl” refers to a cyclopropyl group wherein one or more (e.g., 1 to 5, 1 to 4, 1 to 3, or 1 to 2) hydrogen atoms are replaced by a deuterium atom.
[0064] In many cases, the compounds of this disclosure are capable of forming acid and / or base salts by virtue of the presence of amino and / or carboxyl groups or groups similar thereto.
[0065] Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.
[0066] The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid,gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of NH3. or primary, secondary, tertiary amines, such as salts derived from a N-containing heterocycle, a N-containing heteroaryl, or derived from an amine of formula N(RN)3(e.g.. HN+(RN)3or (alkyl)N+(RN)3) where each RNis independently hydrogen, alkyl, alkenyl, alkynyl. haloalkyl. cycloalkyl, heterocyclyl. aryl, or heteroaryl, wherein each is optionally substituted, such as by one or more (e.g.. 1-5 or 1-3) substituents (e.g.. halo, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or haloalkoxy). Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol. piperazine, piperidine, morpholine, N- ethylpiperidine, and the like.
[0067] The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom’s normal valence is not exceeded. The one or more substituents include, but are not limited to, acyl, alkenyl, alkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, amidino, amido, amino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, guanidino, halo, haloalkoxy, haloalkoxyalkyl, haloalkyl, heteroalkyl, heteroaryl, heterocyclyl, hydrazino, hydroxy, hydroxyalkyl, imido, imino, nitro, oxo, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, thione, or combinations thereof.
[0068] Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl)substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted. For example, in some embodiments, the term “substituted alkyl” refers to an alkyl group having one or more substituents including hydroxy, halo, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted withhalo, alkyl, haloalkyl, hydroxy, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is unsubstituted.
[0069] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
[0070] A “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
[0071] As used herein, when a ring is described as being “aromatic,” it means the ring has a continuous, delocalized 7t-electron system. Typically, die number of out of plane ^-electrons corresponds to the Hiickel rule (4n+2). Examples of such rings include: benzene, pyridine, pyrimidine, pyrazine, pyridazine, pyridone, pyrrole, pyrazole, oxazole, thiazole, isoxazole, isothiazole, and the like. When a ring system comprising at least two rings is described as “aromatic,” it means the ring system comprises one or more aromatic ring(s). Accordingly, when a ring system comprising at least two rings is described as “nonaromatic,” none of the constituent rings of the ring system is aromatic.
[0072] As used herein, when a ring is described as being “partially unsaturated,” it means the ring has one or more additional degrees of unsaturation (in addition to the degree of unsaturation attributed to the ring itself; e.g.. one or more double bonds between constituent ring atoms), provided that the ring is not aromatic. Examples of such rings include: cyclopentene, cyclohexene, cycloheptene, dihydropyridine, tetrahydropyridine, dihydropyrrole, dihydrofuran, dihydrothiophene, and the like. When a ring system comprising at least two rings is described as “partially unsaturated,” it means the ring system comprises one or more partially unsaturated ring(s), provided that none of the constituent rings of the ring system is aromatic.
[0073] As used herein, the term “compound,” is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified. Further, the term “compound” encompasses a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug or solvate thereof. For clarity, the phrase "a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug or solvate thereof " is intended to refer to any one or combination thereof.
[0074] The term “tautomer” as used herein refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium, and it is to be understood that compounds provided herein may be depicted as different tautomers, and when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the disclosure, and the naming of the compounds does not exclude any tautomer.
[0075] The term “GLP-1R” or “GLP-1 receptor” as used herein is meant to include, without limitation, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous, and / or orthologous GLP-1R molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.
[0076] The term “GLP-1 associated disease” as used herein is meant to include, without limitation, all those diseases, disorders, or conditions in which modulating glucagon-like peptide- 1 (GLP-1) receptor signaling can alter the pathology and / or symptoms and / or progression of the disease, disorder, or condition.
[0077] The term “GLP-1 receptor agonist” or “GLP-1 RA” as used herein refers to an agonist of the glucagon-like peptide- 1 (GLP-1) receptor. GLP-1 RAs enhance glucose-dependent insulin secretion; suppress inappropriately elevated glucagon levels, both in fasting and postprandial states; and slow gastric emptying. Karla et al., Glucagon-like peptide- 1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future, Indian J Endocrinol Metab. 2016 Mar-Apr; 20(2): 254-267. GLP-1 RAs have been shown to treat type 2 diabetes. Examples of GLP-1 RAs include, but are not limited to, albiglutide (Tanzeum®), dulaglutide (LY2189265, Trulicity®), efpeglenatide, exenatide (Byetta®, Bydureon®, Exendin-4), liraglutide (Victoza®, NN2211), lixisenatide (Lyxumia®), semaglutide (Ozempic®), tirzepatide, ZP2929, NNC0113-0987, BPL3016, and TT401.
[0078] The term “pharmaceutically acceptable” as used herein indicates that the compound, or salt or composition thereof is compatible chemically and / or toxicologically with the other ingredients comprising a formulation and / or the subject being treated therewith.
[0079] The term “administration” or “administering” refers to a method of giving a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, and the severity of the disease.
[0080] The terms “effective amount” or “effective dosage” or “pharmaceutically effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a chemical entity (e.g., one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof) being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, and can include curing the disease. “Curing” means that the symptoms of active disease areeliminated. The result includes reduction and / or alleviation of tire signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study. In some embodiments, a “therapeutically effective amount” of a compound as provided herein refers to an amount of the compound that is effective as a monotherapy or combination therapy.
[0081] The term “excipient” or “pharmaceutically acceptable excipient” means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In some embodiments, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia. PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007;Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.
[0082] The term “pharmaceutical composition” refers to a mixture of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, as provided herein with other chemical components (referred to collectively herein as “excipients”), such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and / or thickening agents. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.
[0083] The terms “treat,” “treating,” and “treatment,” in the context of treating a disease, disorder, or condition, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof.
[0084] The term “preventing,” as used herein, is tire prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.
[0085] The terms “subject,” “patient,” or “individual,” as used herein, are used interchangeably and refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans. In some embodiments, the term refers to a subject,particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired or needed. In some embodiments, tire subject is a human. In some embodiments, the subject has experienced and / or exhibited at least one symptom of the disease, disorder, or condition to be treated and / or prevented.
[0086] The terms “treatment regimen” and “dosing regimen” are used interchangeably to refer to the dose and timing of administration of each therapeutic agent in a combination.
[0087] The term “pharmaceutical combination,” as used herein, refers to a pharmaceutical treatment resulting from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.
[0088] The term “combination therapy” as used herein refers to a dosing regimen of two different therapeutically active agents (i.e., the components or combination partners of tire combination), wherein the therapeutically active agents are administered together or separately in a manner prescribed by a medical care taker or according to a regulatory agency as defined herein.
[0089] The term “modulate,” “modulating,” or “modulation,” as used herein, refers to a regulation or an adjustment (e.g., increase or decrease) and can include, for example agonism, partial agonism or antagonism.Compounds
[0090] This disclosure relates to methods for treating or preventing Parkinson’s disease using GLP-1 receptor agonists. Exemplary GLP-1 receptor agonists for use in the methods disclosed herein are provided below or can be found in WO 2021 / 155841, WO 2022 / 048665, WO 2022 / 052958, WO 2024 / 169952, WO 2023 / 169456, WO 2024 / 125602, WO 2025 / 045208, PCT / US2024 / 061069, WO 2025 / 006921, WO 2021 / 160127, WO 2021 / 219019, WO 2022 / 028572, WO 2022 / 042691, WO 2022 / 078407, WO 2022 / 078380, WO 2023 / 179542, WO 2023 / 198140, WO 2023 / 138684, WO 2023 / 151575, WO 2023 / 151574, WO 2024 / 131869, or WO 2024 / 138048. In certain embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is provided in WO 2021 / 155841, WO 2022 / 048665, WO 2022 / 052958, WO 2024 / 169952, WO 2023 / 169456, WO 2024 / 125602, WO 2025 / 045208, PCT / US2024 / 061069. or WO 2025 / 006921. In certain embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is provided in WO 2021 / 160127, WO 2021 / 219019. WO 2022 / 028572, WO 2022 / 042691, WO 2022 / 078407, WO 2022 / 078380, WO 2023 / 179542, WO 2023 / 198140, WO 2023 / 138684, WO 2023 / 151575, WO 2023 / 151574. WO 2024 / 131869. or WO 2024 / 138048.
[0091] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula I:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, wherein:Q2is N or CRQA;RQBis -S(O)(NRa)Rbor -P(O)Ra’Rb’;Rais hydrogen, cyano, Ci-s alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of halo, oxo, Ci-e alkoxy, C3-6 cycloalkyl, and heteroaryl, C3-6 cycloalkyl optionally substituted with 1 -3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1-3 alkyl;Rbis C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1-3 alkyl;or Raand Rbtaken together with the atoms to which each is attached form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-3 independently selected C1-6 alkyl;Ra’ and Rb’ are independently selected from the group consisting of Ci-e alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and Ce-io aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; orRa’ and Rb’ taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra’ and Rb’) are heteroatoms each independently selected from the group consisting of: 0, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected Ci-e alkyl;each RQAis independently hydrogen, halo, cyano, hydroxy, -NRcRd, -C(O)NRcRd, -S(O)0-2Re, Ci-6 alkyl optionally substituted with 1-6 independently selected Rf, Ci-6 alkoxy optionally substituted with 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and Ci-6 alkoxy, 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-6 alkyl and -C(O)(Ci-e alkyl), Ce-io aryl optionally substituted with 1-3 independently selected -C(O)(Ci-6 alkyl), and 5-10 membered heteroaryl optionally substituted with 1-6 independently selected Rg;or Raor Rband an adjacent R°Aare taken together with the atom to which each is attached to form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-2 independently selected Rh;q is 0, 1, 2, 3, 4, or 5;each RAis independently halo, Ci-6 alkyl. Ci-e haloalkyl, Ci-e alkoxy. or C3-s cycloalkyl;R3is hydrogen or C1-6 alkyl optionally substituted with 1-6 substituents independently selected from the group consisting of halo, hydroxy, and C1-6 alkoxy;R9is -C(O)OR9a, -C(O)NR9aR9b, 5-6 membered heteroaryl optionally substituted with 1-3 independently selected R9c, 4-6 membered heterocyclyl optionally substituted with 1-3 independentlyselectedX1is O or S;R9ais hydrogen or C1-6 alkyl;R9bis hydrogen, Ci-e alkyl, -C(O)(Ci-6 alkyl). -S(0)o-2< Ci-6 alkyl), or cyano;each R9cis independently hydrogen, oxo, C1-6 alkyl optionally substituted with 1-6 independently selected halo and C1-6 alkoxy, or -C(O)(Ci-e alkyl);v is 0, 1, 2, or 3;each RCais independently halo, cyano, C1-6 alkyl. C1-6 haloalkyl. C1-6 alkoxy, or NRcRd; or a pair of RCaon the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including 3-8 ring atoms;each Rcand Rdare each independently hydrogen, Ci-e alkyl, -C(O)(Ci-e alkyl),-C(O)(C3-6 cycloalkyl), -C(O)O(Ci-e alkyl), -S(O)i-2(Ci-6 alkyl), or -S(O)i-2(C3-6 cycloalkyl), wherein the C1.6 alkyl, -C(O)(Ci-6alkyl), -C(O)(C3-6cycloalkyl), -C(O)O(Ci-6alkyl), -S(O)i.2(Cwalkyl), and -S(O)i-2(C3-6 cycloalkyl) are each optionally substituted with 1-6 substituents independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy;each Reis independently hydrogen, Ci-e alkyl, or Ci-6 haloalkyl;w is 0, 1, 2, or 3;each R1f is independently C1-6 alkyl, wherein each C1-6 alkyl is independently optionally substituted with 1-6 independently selected Rf;each Rfis independently halo, hydroxy, -NRcRd, Ci-6 alkoxy, Ci-e haloalkoxy, or 3-12 membered heterocyclyl which is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxy, Ci-6 alkyl, and 3-12 membered heterocyclyl;each Rgis independently Ci-6 alkyl, Ci-6 alkoxy, -NRcRd, or 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-6 alkyl and -C(O)Ci-6 alkyl; andeach Rhis independently halo, cyano, hydroxy, Ci-6 alkyl, Ci-e haloalkyl, -NH2, -NH(CI-3 alkyl), -N(C1-3 alkyl)2, C1-3 alkoxy, or C1-3 haloalkoxy.
[0092] In some embodiments of the compounds disclosed herein, one or more hydrogens have been replaced by deuterium.
[0093] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula la:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0094] In some embodiments, RQBis -S(O)(NRa)Rb.
[0095] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula II:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof..
[0096] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula II:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, wherein:Q2is N or CRQA;Rais hydrogen, cyano, Ci-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of halo, oxo, Ci-e alkoxy, C3-6 cycloalkyl, and heteroaryl, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1.3 alkyl;Rbis C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy. C3-6 cycloalkyl, and halo, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1-3 alkyl;or Raand Rbtaken together with the atoms to which each is attached form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-3 independently selected Ci-6 alkyl;each RQAis independently hydrogen, halo, cyano, hydroxy, -NRcRd, -C(O)NRcRd, -S(O)0-2Re, Ci-6 alkyl optionally substituted with 1-6 independently selected Rf, Ci-e alkoxy optionally substituted with 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and Ci-e alkoxy, 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-e alkyl and -C(O)(Ci-s alkyl), Ce-io aryl optionally substituted with 1-3 independently selected -C(O)(Ci.e alkyl), and 5-10 membered heteroaryl optionally substituted with 1-6 independently selected Rg;or Raor Rband an adjacent RQAare taken together with the atom to which each is attached to form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-2 independently selected Rh;q is 0, 1, 2, 3, 4, or 5;each RAis independently halo, Ci-6 alkyl, Ci-6 haloalkyl, Ci-6 alkoxy, or C3-6 cycloalkyl;R3is hydrogen or C1-6 alkyl optionally substituted with 1-6 substituents independently selected from the group consisting of halo, hydroxy, and Ci-6 alkoxy;R9is -C(O)OR9a, -C(O)NR9aR9b, 5-6 membered heteroaryl optionally substituted with 1-3 independently selected R9c, 4-6 membered heterocyclyl optionally substituted with 1 -3 independentlyselectedX1is O or S;R9ais hydrogen or Ci-6 alkyl;R9bis hydrogen, Ci-6 alkyl, -C(O)(Ci-6 alkyl), -S(0)o-2(Ci-6 alkyl), or cyano;each R9cis independently hydrogen, oxo, Ci-6 alkyl optionally substituted with 1-6 independently selected halo and Ci-6 alkoxy, or -C(O)(Ci-6 alkyl);each Rcand Rdare each independently hydrogen, Ci-6 alkyl, -C(O)(Ci-6 alkyl),-C(O)(C3-6 cycloalkyl), -C(O)O(Ci-6 alkyl), -S(O)i.2(Ci-6 alkyl), or -S(O)i.2(C3-6 cycloalkyl), wherein the Ci-e alkyl, -C(O)(Ci-6 alkyl), -C(O)(C3-6 cycloalkyl), -C(O)O(Ci-6 alkyl), -S(O)1-2(Ci-6 alkyl), and -S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with 1-6 substituents independently selected from the group consisting of hydroxy, halo, and Ci-6 alkoxy;each Reis independently hydrogen, Ci-e alkyl, or Ci-6 haloalkyl;w is 0, 1, 2, or 3;each Rlfis independently Ci-e alkyl, wherein each Ci-6 alkyl is independently optionally substituted with 1-6 independently selected Rf;each Rfis independently halo, hydroxy, -NRcRd, Ci-6 alkoxy, Ci-6 haloalkoxy, or 3-12 membered heterocyclyl which is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxy, Ci-6 alkyl, and 3-12 membered heterocyclyl;each Rgis independently Ci-6 alkyl, Ci-6 alkoxy, -NRcRd, or 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-6 alkyl and -C(O)Ci-6 alkyl; andeach Rhis independently halo, cyano, hydroxy, Ci-6 alkyl, Ci-6 haloalkyl, -NH2, -NH(CI-3 alkyl), -N(C1-3 alkyl)2, C1-3 alkoxy, or C1-3 haloalkoxy.
[0097] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula Ila:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, wherein:Rais hydrogen, cyano, C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of halo, oxo, Ci-s alkoxy, C3-6 cycloalkyl, and heteroaryl, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1.3 alkyl;Rbis C1-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo, C3-6 cycloalkyl optionally substituted with 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1-3 alkyl;RQAis hydrogen, halo, cyano, hydroxy, -NRcRd, -C(O)NRcRd, -S(O)0.2Re, Ci-e alkyl optionally substituted with 1-6 independently selected Rf, Ci-6 alkoxy optionally substituted with 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and Ci-6 alkoxy, 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-6 alkyl and -C(O)(Ci-6 alkyl), Ce-io aryl optionally substituted with 1-3 independently selected -C(O)(Ci-6 alkyl), and 5-10 membered heteroaryl optionally substituted with 1-6 independently selected Rg;each Rcand Rdare each independently hydrogen, Ci-e alkyl, -C(O)(Ci-e alkyl),-C(O)(C3-6 cycloalkyl), -C(O)O(Ci-e alkyl), -S(O)i-2(Ci-6 alkyl), or -S(O)i-2(C3-6 cycloalkyl), wherein the Ci-e alkyl, -C(O)(Ci-6alkyl), -C(O)(C3.6cycloalkyl), -C(O)O(Ci.6alkyl), -S(O)i.2(Cw alkyl), and -S(O)i-2(C3-6 cycloalkyl) are each optionally substituted with 1-6 substituents independently selected from the group consisting of hydroxy, halo, and Ci-6 alkoxy;each Reis independently hydrogen, Ci-e alkyl, or Ci-e haloalkyl; andeach Rgis independently Ci-e alkyl, Ci-6 alkoxy, -NRcRd, or 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of Ci-6 alkyl and -C(O)Ci-e alkyl.
[0098] In some embodiments, RQAis hydrogen, halo, -NRcRd, or Ci-6 alkyl. In some embodiments, RQAis hydrogen, halo, -NHCH3, or methyl.
[0099] In some embodiments, Rais hydrogen or Ci-6 alkyl. In some embodiments, Rais hydrogen, methyl, or ethyl.
[0100] In some embodiments, Rbis Ci-6 alkyl or C3-6 cycloalkyl. In some embodiments, Rbis methyl, ethyl, cyclopropyl, or cyclobutyl.
[0101] In some embodiments, Rais hydrogen or Ci-6 alkyl; and Rbis Ci-6 alkyl or C3-6 cycloalkyl.
[0102] In some embodiments, Rais hydrogen, methyl, or ethyl; and Rbis methyl, ethyl, cyclopropyl, or cyclobutyl.
[0103] In some embodiments, Rais hydrogen or Ci-6 alkyl.
[0104] In some embodiments, Rbis Ci-6 alkyl or C3-6 cycloalkyl.
[0105] In some embodiments, Rais hydrogen, methyl, or ethyl; and Rbis methyl, ethyl, cyclopropyl, or cyclobutyl.
[0106] In some embodiments, Q2is CH.
[0107] In some embodiments, each RQAis independently hydrogen, halo, -NHCH3, or methyl.
[0108] In some embodiments, RQBis -P(O)Ra’Rb’.
[0109] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is a compound of Formula III:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0110] In some embodiments, Ra’ and Rb’ are each independently methyl, ethyl, or cyclopropyl.
[0111] In some embodiments, Ra’ and Rb’ are each independently C1-3 alkyl.
[0112] In some embodiments, Ra’ and Rb’ are each ethyl.
[0113] In some embodiments, Ra’ is C1-3 hydroxyalkyl or cyclopropyl optionally substituted with OH. In some embodiments, Ra’ is C1-3 hydroxyalkyl. In some embodiments. Ra’ is cyclopropyl optionally substituted with OH.embodiments, Rb’ is ethyl.
[0115] In some embodiments, R3is methyl.
[0116] Some embodiments provide for a compound selected Table 1, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.GSBR-0047-WO
[0117] In some embodiments, the GLP-1 receptor modulator is selected from Table 2, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.GSBR-0047-WOGSBR-0047-WOGSBR-0047-WOGSBR-0047-WOGSBR-0047-WOGSBR-0047-WOGSBR-0047-WO
[0118] The compounds of Formula I, II, and III, as well as those in Table 1 and Table 2, can be provided following procedures described in WO 2021 / 155841 and WO 2024 / 169952, each of which is hereby incorporated by reference in its entirety.
[0119] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is Compound 12:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0120] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein isCompound 17:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0121] In some embodiments, the GLP-1 receptor agonist for use in the methods disclosed herein is Compound 18:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
[0122] It will further be appreciated that a compound disclosed herein or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present disclosure. For example, compounds disclosed herein can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, isopropanol, and the like.Pharmaceutical Compositions and Administration
[0123] When employed as pharmaceuticals, compounds as described herein (e.g., one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof) can be administered in the form of a pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, dependingupon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Oral administration can include a dosage form formulated for once-daily or twice-daily (BID) administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or can be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
[0124] Also provided herein are pharmaceutical compositions which contain, as the active ingredient, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, in combination with one or more pharmaceutically acceptable excipients (carriers). For example, a pharmaceutical composition prepared using one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof.
[0125] In one embodiment, provided is a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, as disclosed herein, and a pharmaceutically acceptable excipient. In one embodiment, provided is a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, as disclosed herein, and a pharmaceutically acceptable excipient, wherein a compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is present in the pharmaceutical composition in an amount greater than about 0.1%, greater than about 1%, greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 25%, greater than about 35%, or greater than about 40%, or greater than about 45%, or greater than about 50%, or greater than about 55%, or greater than about 60%, or greater than about 65%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95% purity, or about 40%, or about 45%, or about 50%, or about 55%, or about 60%, or about 65%, or about 70%, or about 75%, or about 80%, or about 85%, or about 90%, or about 95%, by weight.
[0126] In some embodiments, the composition is suitable for topical administration. In making the compositions provided herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the formof tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is formulated for oral administration. In some embodiments, the composition is a solid oral formulation. In some embodiments, the composition is formulated as a tablet or capsule.
[0127] Further provided herein are pharmaceutical compositions containing one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof with a pharmaceutically acceptable excipient. Pharmaceutical compositions containing one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof as the active ingredient can be prepared by intimately mixing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). In some embodiments, the composition is a solid oral composition.
[0128] Further provided herein are pharmaceutical compositions containing one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, with a pharmaceutically acceptable excipient.
[0129] Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers can be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
[0130] Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1 -3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.
[0131] In some embodiments, the compound or pharmaceutical composition can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, selfemulsifying drug delivery systems (SEDDS) such as d-a-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogenphosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene -block polymers, and wool fat. Cyclodextrins such as a-, 0, and y-cyclodextrin, or chemically modified derivatives such as hydroxy alkylcyclodextrins, including 2- and 3-hydroxypropyl-0 -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a chemical entity as described herein in the range of 0.005% to 100% with the balance made up from non-toxic excipient may be prepared. The contemplated compositions may contain 0.001%-100% of a chemical entity provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, London. UK. 2012).
[0132] In some embodiments, the compounds and pharmaceutical compositions described herein or a pharmaceutical composition thereof can be administered to patient in need thereof by any accepted route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric. intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary. intrasinal. intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal (e.g., intranasal), nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral and vaginal. In some embodiments, a route of administration is parenteral (e.g., intratumoral).
[0133] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or pharmaceutical compositions thereof can be formulated for parenteral administration, e.g., formulated for injection via the intraarterial, intrastemal, intracranial, intravenous, intramuscular, sub-cutaneous, or intraperitoneal routes. For example, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified. The preparation of such formulations will be known to those of skill in the art in light of the present disclosure. In some embodiments, devices are used for parenteral administration. For example, such devices may include needle injectors, microneedle injectors, needle-free injectors, and infusion techniques.
[0134] In some embodiments, the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propyleneglycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form must be sterile and must be fluid to the extent that it may be easily injected. In some embodiments, the form should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
[0135] In some embodiments, the carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. In some embodiments, the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. In some embodiments, the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and tire like. In some embodiments, isotonic agents, for example, sugars or sodium chloride are included. In some embodiments, prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0136] In some embodiments, sterile injectable solutions are prepared by incorporating one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. In some embodiments, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In some embodiments, sterile powders are used for the preparation of sterile injectable solutions. In some embodiments, the methods of preparation are vacuum-drying and freeze-drying teclmiques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.
[0137] In some embodiments, pharmacologically acceptable excipients usable in a rectal composition as a gel, cream, enema, or rectal suppository, include, without limitation, any one or more of cocoa butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), glycerine, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol, Vaseline, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil. aerosol, parabens in phenoxy ethanol, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, diethylamine, carbomers, carbopol, methyloxybenzoate, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxymetabisulfite, sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methyl sulfonyl methane (MSM), lactic acid, glycine, vitamins, such as vitamin A and E and potassium acetate.
[0138] In some embodiments, suppositories can be prepared by mixing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutical compositions as described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound. In some embodiments, compositions for rectal administration are in the form of an enema.
[0139] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, as described herein or a pharmaceutical composition thereof is formulated for local delivery to the digestive or GI tract by way of oral administration (e.g., solid or liquid dosage forms.).
[0140] In some embodiments, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and / or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearale, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. For example, in the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. In some embodiments, solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
[0141] In some embodiments, the pharmaceutical compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In some embodiments, another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG’S, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). In some embodiments, unit dosage forms in which one or more compounds and pharmaceutical compositions as provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of eachdrug; two-layer tablets; two-compartment gel caps, etc. In some embodiments, enteric coated or delayed release oral dosage forms are also contemplated.
[0142] In some embodiments, other physiologically acceptable compounds may include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing die growth or action of microorganisms. For example, various preservatives are well known and include, for example, phenol and ascorbic acid.
[0143] In some embodiments, the excipients are sterile and generally free of undesirable matter. For example, these compositions can be sterilized by conventional, well-known sterilization techniques. In some embodiments, for various oral dosage form excipients such as tablets and capsules, sterility is not required. For example, the United States Pharmacopeia / National Formulary (USP / NF) standard can be sufficient.
[0144] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or a pharmaceutical composition thereof is formulated for ocular administration. In some embodiments, ocular compositions can include, without limitation, one or more of any of the following: viscogens (e.g., carboxymethylcellulose, glycerin, polyvinylpyrrolidone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymers), cyclodextrins); preservatives (e.g., benzalkonium chloride, EDTA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.)).
[0145] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or a pharmaceutical composition thereof is formulated for topical administration to die skin or mucosa (e.g., dermally or transdermally). In some embodiments, topical compositions can include ointments and creams. In some embodiments, ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. In some embodiments, creams containing the selected active agent are typically viscous liquid or semisolid emulsions, often either oil-in-water or water-in-oil. For example, cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase. For example, die oil phase, also sometimes called the “internal” phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, aldiough not necessarily, exceeds the oil phase in volume, and generally contains a humectant. In some embodiments, the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. In some embodiments, as with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing.
[0146] In any of the foregoing embodiments, pharmaceutical compositions as described herein can include one or more one or more of the following: lipids, interbilayer crosslinked multilamellar vesicles, biodegradeable poly(D, L-lactic-co-glycolic acid) (PLGA)-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.
[0147] The amount of the compound in a pharmaceutical composition or formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. In one embodiment, the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations are described below.Formulation Example 1 - Tablet formulation
[0148] The following ingredients are mixed intimately and pressed into single scored tablets.Formulation Example 2 - Capsule formulation
[0149] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsuleFormulation Example 3 - Suspension formulation
[0150] The following ingredients are mixed to form a suspension for oral administration.Formulation Example 4 - Injectable formulation
[0151] The following ingredients are mixed to form an injectable formulation.Formulation Example 5 - Suppository Formulation
[0152] A suppository of total weight 2.5 g is prepared by mixing the compound of this disclosure with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:
[0153] In some embodiments, the dosage for one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or solvate thereof, is determined based on a multiple factors including, but not limited to, type, age, weight, sex, medical condition of the patient, severity of the medical condition of the patient, route of administration, and activity of the compound, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof. In some embodiments, proper dosage for a particular situation can be determined by one skilled in the medical arts. In some embodiments, the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.
[0154] In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is administered at a dose from about 0.01 to about 1000 mg. For example, from about 0.1 to about 30 mg, about 10 to about 80 mg. about 0.5 to about 15 mg, about 50 mg to about 200 mg. about100 mg to about 300 mg, about 200 to about 400 mg, about 300 mg to about 500 mg, about 400 mg to about 600 mg, about 500 mg to about 800 mg, about 600 mg to about 900 mg, or about 700 mg to about 1000 mg. In some embodiments, the dose is a therapeutically effective amount.
[0155] In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, as described herein is administered at a dosage of from about 0.0002 mg / Kg to about 100 mg / Kg (e.g., from about 0.0002 mg / Kg to about 50 mg / Kg; from about 0.0002 mg / Kg to about 25 mg / Kg; from about 0.0002 mg / Kg to about 10 mg / Kg; from about 0.0002 mg / Kg to about 5 mg / Kg; from about 0.0002 mg / Kg to about 1 mg / Kg; from about 0.0002 mg / Kg to about 0.5 mg / Kg; from about 0.0002 mg / Kg to about 0.1 mg / Kg; from about 0.001 mg / Kg to about 50 mg / Kg; from about 0.001 mg / Kg to about 25 mg / Kg; from about 0.001 mg / Kg to about 10 mg / Kg; from about 0.001 mg / Kg to about 5 mg / Kg; from about 0.001 mg / Kg to about 1 mg / Kg; from about 0.001 mg / Kg to about 0.5 mg / Kg; from about 0.001 mg / Kg to about 0.1 mg / Kg; from about 0.01 mg / Kg to about 50 mg / Kg; from about 0.01 mg / Kg to about 25 mg / Kg; from about 0.01 mg / Kg to about 10 mg / Kg; from about 0.01 mg / Kg to about 5 mg / Kg; from about 0.01 mg / Kg to about 1 mg / Kg; from about 0.01 mg / Kg to about 0.5 mg / Kg; from about 0.01 mg / Kg to about 0.1 mg / Kg; from about 0.1 mg / Kg to about 50 mg / Kg; from about 0.1 mg / Kg to about 25 mg / Kg; from about 0.1 mg / Kg to about 10 mg / Kg; from about 0.1 mg / Kg to about 5 mg / Kg; from about 0.1 mg / Kg to about 1 mg / Kg; from about 0.1 mg / Kg to about 0.5 mg / Kg). In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, as described herein is administered as a dosage of about 100 mg / Kg.
[0156] In some embodiments, the foregoing dosages of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month).
[0157] In some embodiments, the period of administration of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, as described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, one or more compounds asdisclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is administered to a patient for a period of time followed by a separate period of time where administration of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is stopped. In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof is administered for a first period and a second period following the first period, with administration stopped during the second period, followed by a third period where administration of one or more compounds as disclosed herein or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is started and then a fourth period following the third period where administration is stopped. For example, the period of administration of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, followed by a period where administration is stopped is repeated for a determined or undetermined period of time. In some embodiments, a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.
[0158] In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is orally administered to the patient one or more times per day (e.g., one time per day, two times per day, three times per day, four times per day per day or a single daily dose).
[0159] In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is administered by parenteral administration to the patient one or more times per day (e.g., 1 to 4 times, one time per day, two times per day, three times per day, four times per day or a single daily dose).
[0160] In some embodiments, one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, is administered by parenteral administration to the patient weekly.
[0161] In some embodiments, the GLP-1 receptor agonist, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, isadministered to the subject daily, every other day, every two days, every three days, once per week, twice per week, once every two weeks, or once monthly.
[0162] In some embodiments, the method provides further comprising administering an additional therapy. In some embodiments, the GLP-1 receptor modulator is selected from tirzepatide (Mounjaro®, Zepbound®), exenatide (Byetta®, Bydureon®, Exendin-4), lixisenatide (Lyxumia®), liraglutide (Victoza®, NN2211), dulaglutide (LY2189265, Trulicity®), albiglutide (Tanzeum®), semaglutide (Wegovy®, Rybelsus®, Ozempic®), aleniglipron (GSBR-1290), retatrutide (LY3437943), mazdutide (LY3305677), efpeglenatide (HM11260C), taspoglutide (R1583, BIM51077, ITM077), survodutide (BI456906), cotadutide (MEDI0382), pemvidutide (ALT-801), efinopegdutide (MK-6024), efocipegtrutide (HM15211), pegloxenatide (PEX168), pegapamodutide (LY2944876), albenatide (CJC1134PC), utreglutide (GL0034), ZP2929, NNC0113-0987, BPL3016, TT401, SAR441255, BI-456906, ALT-801, AC-3174, SAR-425899, YH-25723, YH-25724, YH-22241, YH-GLP1, RPC-8844, PB-718, NN-6177, CT-388, CT-868, XW003, XW004, CJC-1134, CJC-1131, AMG133, DD-01, DD-03, DD-14, DD-15, ID110521156, TERN-601, MDR-001, HPG5119, ECC5004, VK2735, orforglipron (LY3502970), danuglipron (PF06882961), lotiglipron (PF07081532), CT-996, HRS-7535, V-0219, XW014, LSN3318839, TTP273, HS-10535, MET-097i, GZR18, VRB-101, GS-4571, RGT-075, VCT220. PF-06954522, ASC-30, HDM1002, HS-10501, HSK-34890, SAL-0112, THDBH110, DA-3021688, APH01727. GMA102, AZD-9550, NLY01, GMA105, dapiglutide (ZP7570), UBT25L DR10624, GMA106, HSK34890, LY3549492. amycretin (NN9487), NN-9490, NN-9542, NN-9650, avexitide, lixisenatide, utreglutide, efpeglenatide. andZT-002.Methods of Treatment
[0163] In some embodiments, this disclosure features methods for treating or preventing Parkinson’s Disease (PD) in a subject.
[0164] In some embodiments, provided herein is a method for protecting dopaminergic neuron from being damaged, or preventing loss of dopaminergic neuron from a subject.
[0165] In some embodiments, provided herein is a method for recovering dopaminergic neuron activity, or increasing dopaminergic neuron activity in a subject suffering from PD.
[0166] In some embodiments, provided herein is a method for improving motor activity or motor control in a subject suffering from PD.
[0167] The methods described herein comprises administering to a patient in need thereof an effective amount of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0168] In some embodiments, this disclosure features methods for treating or preventing Parkinson’s Disease (PD) in a subject, comprising administering to a patient in need thereof an effective amount ofone or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0169] In some embodiments, provided herein is a method for protecting dopaminergic neuron from being damaged, or preventing loss of dopaminergic neuron from a subject, comprising administering to a patient in need thereof an effective amount of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0170] In some embodiments, provided herein is a method for recovering dopaminergic neuron activity, or increasing dopaminergic neuron activity in a subject suffering from PD, comprising administering to a patient in need thereof an effective amount of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0171] In some embodiments, provided herein is a method for improving motor activity or motor control in a subject suffering from PD, comprising administering to a patient in need thereof an effective amount of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0172] In some embodiments, provided herein is a method for reducing the risk (e.g., by about at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%) of Parkinson’s Disease (PD) in a patient in need thereof, the method comprising administering to the patient an effective amount of one or more compounds as disclosed herein, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, or a pharmaceutical composition as disclosed herein.
[0173] In some embodiments, the subject or patient has previously been treated with drugs for PD, such as levodopa (L-DOPA), carbidopa, baclofen, acamprosate, cinacalcet, mexiletine, torasemide, sulfisoxazole, acamprosate, pergolide, cabergoline, dopamine agonists such as pramipexole, ropinirole and rotigotine, COMT inhibitors such as Entacapone or tolcapone, apomorphine or lisuride and monoamine oxidase-B inhibitors (involved in the catabolic breakdown of dopamine) such as selegiline or rasagiline, catechol-O-methyl transferase inhibitors such as entacapone, or anticholinergics and nicotinic acetylcholine receptor agonists that target apoptosis (omigapil, CEP-1347), glutamate receptors, adenosine A2A receptor, calcium channels (isradipine), growth factors (GDNF), alpha-synuclein or inflammation.
[0174] In some embodiments, the subject or patient has previously been treated with one or more of PD therapy, such as drug therapy, gene therapy, or neural transplantation (e.g. cell transplantation or stemcell therapy), surgical therapy (deep brain stimulation or lesioning procedure), physical and occupational therapy, speech and swallowing therapy, psychological and supportive therapy (psychotherapy), alternative therapies (e.g. acupuncture, yoga or tai chi).
[0175] In some embodiments, the subject or patient has not previously been treated with an anti-PD drug (drug-naive patients). Thus, in an embodiment, the therapies described herein may be used in naive patients.
[0176] There are three major types of Parkinson’s disease: idiopathic, postencephalitic, and drug-induced. Parkinson’s diseases may also result from arteriosclerosis, may follow poisoning by carbon monoxide or manganese intoxication, or may result from syphilis or the development of tumors.Although Parkinsonian patients can be separated into clinical groups on the basis of cause of the disease, it is nevertheless likely that the mechanisms producing the symptoms have a common origin. Either the substrantia nigra is damaged, as occurs in idiopathic and postencephalitic cases, or the activity of its cells is blocked or cells are killed, as occurs in drug-induced parkinsonism. The cells of the substantia nigra contain a dark pigment in Parkinson's disease that is depigmented by degeneration of the melatonin-containing neurons of the area. The cells of the substantia nigra are the point of origin of fibers that go to the basal ganglial frontal cortex and to the spinal cord. The neurotransmitter at the synapses of these projections is dopamine. It has been demonstrated by bioassay of the brains of deceased parkinsonian patients, and by analysis of the major metabolite of dopamine, homovanallic acid, which is excreted in the urine, that the amount of brain dopamine is reduced by over 90% and is often reduced to undetectable amounts. Thus, the cause of Parkinson's disease has been identified with some certainty as a lack of dopamine or, in drug-induced cases, with a lack of dopamine action.
[0177] In some embodiments, the compounds and pharmaceutical compositions described herein are useful in improving learning and memory by enhancing neuronal plasticity and facilitation of cellular differentiation, and also in preserving dopamine neurons and motor function in Morbus Parkinson.
[0178] In some embodiments, the methods described herein further include the step of identifying a patient (e.g., a subject) in need of such treatment (e.g., by way of motor symptoms, biomarkers, behavior or cognition index, dopamine transporter imaging, MRI or CT scan of the brain, levodopa challenge, or other conventional method known in the art).
[0179] Diagnosis of Parkinson’s Disease involves a combination of clinical evaluation and diagnostic tools. A neurologist assesses motor symptoms such as tremors, rigidity, and bradykinesia through a neurological exam and medical history review. Imaging tests, like MRI or CT scans, help rule out other conditions, while DaTscan can visualize dopamine transporter levels. Biomarkers, such as specific proteins in cerebrospinal fluid and genetic markers, are also used. Additionally, observing a patient’s response to dopaminergic medication, olfactory testing for loss of smell, and neuropsychological tests for cognitive function contribute to the diagnosis, as there is no single definitive test for Parkinson's disease.
[0180] In some embodiments, the methods described herein further include the step of identifying a patient or subject that has PD or at risk of PD. A patient at risk of Parkinson's disease is someone who is more likely to develop the disorder due to a combination of factors, including older age (especially over 60), genetic predispositions such as family history or specific mutations, environmental exposures to toxins like pesticides, male gender, history of head injuries, certain medical conditions, and lifestyle factors like low physical activity. Additionally, advancements in diagnostic methods now include the use of biomarkers, which can aid in identifying early signs of Parkinson's disease before clinical symptoms appear, thereby assisting in early monitoring and potential intervention strategies.
[0181] In some embodiments, the compounds and pharmaceutical compositions described herein can reduce body weight (e.g., excess body weight) prevent body weight gain, induce weight loss, decrease body fat, or reduce food intake in a patient (e.g., a patient in need thereof) who has PD or at risk of PD.
[0182] In some embodiments, a behavioral assessment of Parkinson’s disease (PD) and treatment efficacy of PD in an animal model can include pole test, rotarod test, and open field test for evaluating motor function and activity of the animal. The pole test was designed to measure manual dexterity, limb coordination, and upper-body motor function, particularly sensitive to deficits in dopamine-dependent motor control. The climbing duration is a key parameter to evaluate the animal’s capability to complete the task that have impaired forelimb coordination and strength, reflecting dopamine depletion in the nigrostriatal pathway. The rotarod test evaluates balance, motor coordination, and motor learning, focusing on hindlimb and core stability. Latency to fall (time until tire animal loses balance and falls off the rod) is a parameter reflecting motor deficits in maintaining posture and responding to rotational movement. The open field test assesses general motor activity, exploratory behavior, and anxiety-like traits, providing a broad measure of spontaneous movement. Distance traveled, speed, central zone distance, and central zone entrance are parameters to evaluate the overall activity and movement patterns.Combination Therapy
[0183] In some embodiments, this disclosure contemplates both monotherapy regimens as well as combination therapy regimens.
[0184] In some embodiments, the methods described herein can further include administering one or more additional therapies (e.g., one or more additional therapeutic agents and / or one or more therapeutic regimens) in combination with administration of the compounds described herein.
[0185] In some embodiments, the methods described herein include administering a compound described herein in combination with one or more of PD therapy, such as drug therapy, gene therapy, or neural transplantation (e.g. cell transplantation or stem cell therapy), surgical therapy (deep brain stimulation or lesioning procedure), physical and occupational therapy, speech and swallowing therapy, psychological and supportive therapy (psychotherapy), alternative therapies (e.g. acupuncture, yoga or tai chi).
[0186] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof can be administered in combination with one or more additional therapeutic agents.
[0187] Representative additional therapeutic agents include, but are not limited to, PD drugs, antiobesity agents, therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents, diuretics, chemotherapeutics, immunotherapeutics, anti-inflammatory drugs, antithrombotic agents, anti-oxidants, therapeutic agents for osteoporosis, vitamins, antidementia drugs, erectile dysfunction drugs, therapeutic drugs for urinary frequency or urinary incontinence, therapeutic agents for NAFLD, therapeutic agents for NASH, therapeutic agents for dysuria and anti-emetic agents.
[0188] The non-limiting examples of the PD drugs include levodopa (L-DOPA), carbidopa, baclofen, acamprosate, cinacalcet, mexiletine, torasemide, sulfisoxazole, acamprosate, pergolide, cabergoline, dopamine agonists such as pramipexole, ropinirole and rotigotine, COMT inhibitors such as Entacapone or tolcapone, apomorphine or lisuride and monoamine oxidase-B inhibitors (involved in the catabolic breakdown of dopamine) such as selegiline or rasagiline, catechol-O-methyl transferase inhibitors such as entacapone, or anticholinergics and nicotinic acetylcholine receptor agonists that target apoptosis (omigapil, CEP-1347), glutamate receptors, adenosine A2A receptor, calcium channels (isradipine), growth factors (GDNF), alpha-synuclein or inflammation.
[0189] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-obesity agents. Non-limiting examples include monoamine uptake inhibitors (e.g., tramadol, phentermine, sibutramine, mazindol, fluoxetine, tesofensine), serotonin 2C receptor agonists (e.g., lorcaserin), serotonin 6 receptor antagonists, histamine H3 receptor modulator, GABA modulator (e.g., topiramate), including GABA receptor agonists (e.g., gabapentin, pregabalin), neuropeptide Y antagonists (e.g., velneperit), cannabinoid receptor antagonists (e.g., rimonabant, taranabant), ghrelin antagonists, ghrelin receptor antagonists, ghrelin acylation enzyme inhibitors, opioid receptor antagonists (e.g., GSK-1521498), orexin receptor antagonists, melanocortin 4 receptor agonists, 110-hydroxy steroid dehydrogenase inhibitors (e.g., AZD-4017, BVT-3498, INCB-13739), pancreatic lipase inhibitors (e.g., orlistat, cetilistat), 03 agonists (e.g., N-5984), diacylglycerol acyltransferase 1 (DGAT1) inhibitors, acetylCoA carboxylase (ACC) inhibitors, stearoyl-CoA desaturated enzyme inhibitors, microsomal triglyceride transfer protein inhibitors (e.g., R- 256918), sodium-glucose cotransporter 2 (SGLT-2) inhibitors (e.g., JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA-7284, ASP1941, remogliflozin), NFK inhibitors (e.g., HE-3286), PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil and fenofibrate), phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate, trodusquemin), GPR119 agonists (e.g., PSN-821, MBX-2982, APD597), glucokinase activators (e.g., piragliatin, AZD-1656,AZD6370, TTP-355, compounds described in W0006 / 112549, W0007 / 028135, W0008 / 047821, W0008 / 050821, W0008 / 136428 and W0008 / 156757), leptin, leptin derivatives (e.g., metreleptin), leptinresistance improving drugs, CNTF (ciliary neurotrophic factor), BDNF (brain-derived neurotrophic factor), cholecystokinin agonists, amylin preparations (e.g., pramlintide, AC-2307), neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36, obineptide, TM-30339, TM-30335), oxyntomodulin (OXM) preparations, appetite suppressants (e.g. ephedrine), FGF21 preparations (e.g., animal FGF21 preparations extracted from the pancreas of bovine or swine; human FGF21 preparations genetically synthesized using Escherichia coli or yeast; fragments or derivatives of FGF21 ), anorexigenic agents (e.g., P-57), human proislet peptide (HIP), famesoid X receptor (FXR) agonist, phentermine, zonisamide, norepinephrine / dopamine reuptake inhibitor, GDF-15 analog, methionine aminopeptidase 2 (MetAP2) inhibitor, diethylpropion, phendimetrazine, benzphetamine, fibroblast growth factor receptor (FGFR) modulator, and AMP-activated protein kinase (AMPK) activator.
[0190] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof can be administered in combination with one or more additional therapeutic agents, wherein the additional therapeutic agent is selected from a compound in WO2021 / 155841.
[0191] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-diabetic agents. Non-limiting examples include insulin and insulin preparations (e.g., animal insulin preparations extracted from the pancreas of bovine or swine; human insulin preparations genetically synthesized using Escherichia coli or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS- 1), oral insulin preparation, synthetic human insulin), insulin sensitizers (e.g., pioglitazone or a salt thereof), biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate)), glucagon analogs (e.g., any of glucagon analogs described, e.g., in WO 2010 / 011439), agents which antagonize the actions of or reduce secretion of glucagon, sulfonylurea agents (e.g., chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide. gliclazide, acetohexamide. glyclopyramide, glybuzole, glyburide), thiazolidinedione agents (e.g. rosiglitazone or pioglitazone), a- glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate), insulin secretagogues, such as prandial glucose regulators (sometimes called “short-acting secretagogues”). e.g., meglitinides (e.g. repaglinide and nateglinide), cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, tacrine). NMDA receptor antagonists, dual GLP-l / GIP receptor agonists (e.g., LBT-2000. ZPD1-70), GLP-1R agonists (e.g., exenatide, liraglutide, albiglutide, dulaglutide. abiglutide, taspoglutide, lixisenatide, semaglutide, AVE-0010, S4P and Boc5), and dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, dutogliptin, gemigliptin, alogliptin, saxagliptin, sitagliptin, linagliptin, berberine, adogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin).
[0192] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating NAFL and NASH. Non-limiting examples include FXR agonists, PF-05221304, a synthetic fatty acid-bile conjugate, an anti-lysyl oxidase homologue 2 (LOXL2) monoclonal antibody, a caspase inhibitor, a MAPK5 inhibitor, a galectin 3 inhibitor, a fibroblast growth factor 21 (FGF21). aniacin analogue, a leukotriene D4 (LTD4) receptor antagonist, an acetyl-CoA carboxylase (ACC) inhibitor, a ketohexokinase (KHK) inhibitor, an apoptosis signal-regulating kinase 1 (ASK1) inhibitor, an ileal bile acid transporter (IBAT) inhibitor, glycyrrhizin, Schisandra extract, ascorbic acid, glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, ascorbic acid, glutathione, vitamin B -complex, glitazones / thiazolidinediones (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteamine, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, vitamin E, tetrahydrolipstatin, milk thistle protein, anti-virals, and anti-oxidants.
[0193] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating diabetic complications. Non-limiting examples include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat), neurotrophic factor and increasing agents thereof (e.g., NGF, NT-3, BDNF, neurotrophic production / secretion promoting agents described in WO01 / 14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxyl)propyl] oxazole), compounds described in W02004 / 039365), PKC inhibitors (e.g., ruboxistaurin mesylate), AGE inhibitors (e.g., ALT946, N-phenacylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine), serotonin and noradrenalin reuptake inhibitors (e.g.. duloxetine). sodium channel inhibitors (e.g., lacosamide). active oxygen scavengers (e.g.. thioctic acid), cerebral vasodilators (e.g.. tiapuride. mexiletine), somatostatin receptor agonists (e.g., BIM23190), and apoptosis signal regulating kinase-1 (ASK-1) inhibitors.
[0194] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating hyperlipidemia. Non-limiting examples include HMG-COA reductase inhibitors (e.g.. pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin. pitavastatin or a salt thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., compounds described in WO97 / 10224, e.g., N-[[(3R,5S)- l-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo- 1.2.3, 5-tetrahydro-4. l-benzoxazepin-3-yl]acetyl]piperidin-4-acetic acid), fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate), anion exchange resin (e.g., colestyramine), nicotinic acid drugs (e.g.. nicomol, niceritrol, niaspan). phytosterols (e.g., soysterol, gamma oryzanol (y-oryzanol)), cholesterol absorption inhibitors (e.g., zechia), CETP inhibitors (e.g., dalcetrapib, anacetrapib) and ω-3 fatty acid preparations (e.g., ω-3-fatty acid ethyl esters 90).
[0195] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-hypertensive agents. Non-limiting examples include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril). angiotensin II antagonists (e.g., candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil). calcium antagonists (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine, cilnidipine) and f-blockers (e.g., metoprolol, atenolol, propranolol, carvedilol. pindolol).
[0196] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as diuretics. Non-limiting examples include xanthine derivatives (e.g., theobromine sodium salicylate, theobromine calcium salicylate), thiazide preparations (e.g., ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penfluthiazide, polythiazide, methyclothiazide), antialdosterone preparations (e.g., spironolactone, triamterene), carbonic anhydrase inhibitors (e.g., acetazolamide) and chlorobenzenesulfonamide agents (e.g., chlortalidone, mefruside, indapamide).
[0197] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as immunotherapeutic agents. Non-limiting examples include microbial or bacterial compounds (e.g., muramyl dipeptide derivative, picibanil), polysaccharides having immunoenhancing activity (e.g., lentinan, sizofiran, krestin), cytokines obtained by genetic engineering approaches (e.g., interferon, interleukin (IL) such as IL-1, IL-2, IL-12), and colony-stimulating factors (e.g., granulocyte colony- stimulating factor, erythropoietin).
[0198] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-thrombotic agents. Non-limiting examples include heparins (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium) warfarin (e.g., warfarin potassium); antithrombin drugs (e.g., aragatroban, dabigatran) FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, betrixaban, YM150, compounds described in W002 / 06234, W02004 / 048363, W02005 / 030740, W02005 / 058823, and W02005 / 113504) thrombolytic agents (e.g., urokinase, tisokinase, alteplase, naleplase, monteplase, pamiteplase), and platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, ethyl icosapentate, beraprost sodium, and sarpogrelate hydrochloride).
[0199] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating osteoporosis. Non-limiting examples include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium, and risedronate disodium. Suitable examples of vitamins include vitamin Bl and vitamin B 12. Suitable examples of erectile dysfunction drugs include apomorphine and sildenafil citrate. Suitable examples of therapeutic agents for urinary frequency or urinary incontinence include flavorxate hydrochloride, oxybutynin hydrochloride and propiverine hydrochloride. Suitable examples of therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs such as aspirin, acetaminophen, indomethacin.
[0200] Other exemplary additional therapeutic agents include agents that modulate hepatic glucose balance (e.g., fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators), agents designed to treat the complications of prolonged hyperglycemia, such as aldose reductase inhibitors (e.g. epalrestat and ranirestat), agents usedto treat complications related to micro-angiopathies, anti-dyslipidemia agents, such as HMG-CoA reductase inhibitors (statins, e.g. rosuvastatin), cholesterol-lowering agents, bile acid sequestrants (e.g., cholestyramine), cholesterol absorption inhibitors (e.g. plant sterols such as phytosterols), cholesteryl ester transfer protein (CETP) inhibitors, inhibitors of the ileal bile acid transport system (IB AT inhibitors), bile acid binding resins, nicotinic acid (niacin) and analogues thereof, anti-oxidants (e.g., probucol), omega-3 fatty acids, antihypertensive agents, including adrenergic receptor antagonists, such as beta blockers (e.g. atenolol), alpha blockers (e.g. doxazosin), and mixed alpha / beta blockers (e.g. labetalol), adrenergic receptor agonists, including alpha-2 agonists (e.g. clonidine), angiotensin converting enzyme (ACE) inhibitors (e.g. lisinopril), calcium channel blockers, such as dihydropridines (e.g. nifedipine), phenylalkylamines (e.g. verapamil), and benzothiazepines (e.g. diltiazem), angiotensin II receptor antagonists (e.g. candesartan), aldosterone receptor antagonists (e.g. eplerenone), centrally acting adrenergic drugs, such as central alpha agonists (e.g. clonidine), diuretic agents (e.g. furosemide), haemostasis modulators, including antithrombotics (e.g., activators of fibrinolysis), thrombin antagonists, factor Vila inhibitors, anticoagulants (e.g., vitamin K antagonists such as warfarin), heparin and low molecular weight analogues thereof, factor Xa inhibitors, and direct thrombin inhibitors (e.g. argatroban), antiplatelet agents (e.g., cyclooxygenase inhibitors (e.g. aspirin)), adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel), phosphodiesterase inhibitors (e.g. cilostazol), glycoprotein IIB / IIA inhibitors (e.g. tirofiban), adenosine reuptake inhibitors (e.g. dipyridamole), noradrenergic agents (e.g. phentermine), serotonergic agents (e.g. sibutramine), diacyl glycerolacyltransferase (DGAT) inhibitors, feeding behavior modifying agents, pyruvate dehydrogenase kinase (PDK) modulators, serotonin receptor modulators, monoamine transmission-modulating agents, such as selective serotonin reuptake inhibitors (SSRI) (e.g. fluoxetine), noradrenaline reuptake inhibitors (NARI), noradrenaline-serotonin reuptake inhibitors (SNRI), and monoamine oxidase inhibitors (MAOI) (e.g. toloxatone and amiflamine), compounds described in W0007 / 013694, W02007 / 01814, W02008 / 093639 and W02008 / 099794, GPR40 agonists (e.g., fasiglifam or a hydrate tliereof, compounds described in W02004 / 041266, W02004 / 106276, W02005 / 063729, W02005 / 063725, W02005 / 087710, W02005 / 095338, W02007 / 013689 and W02008 / 001931). SGLT1 inhibitors, adiponectin or agonist thereof, IKK inhibitors (e.g., AS-2868), somatostatin receptor agonists. ACC2 inhibitors, cachexia-ameliorating agents, such as a cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g.. megestrol acetate), glucocorticoids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents, agents for improving fat metabolism (e.g., eicosapentaenoic acid), growth hormones, IGF-1. antibodies against a cachexia-inducing factor TNF-a, LIF, IL -6. and oncostatin M, metabolismmodifying proteins or peptides such as glucokinase (GK). glucokinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor a (PPARa), MC4r agonists, insulin receptor agonist, PDE 5 inhibitors, glycation inhibitors (e.g., ALT-711). nerve regeneration-promoting drugs (e.g., Y-128, VX853, prosaptide), antidepressants (e.g., desipramine, amitriptyline, imipramine), antiepileptic drugs (e.g., lamotrigine, trileptal, keppra, zonegran, pregabalin,harkoseride, carbamazepine), antiarrhythmic drugs (e.g., mexiletine), acetylcholine receptor ligands (e.g., ABT-594), endothelin receptor antagonists (e.g., ABT-627), narcotic analgesics (e.g., morphine), a2 receptor agonists (e.g., clonidine), local analgesics (e.g., capsaicin), antianxiety drugs (e.g., benzothiazepine), phosphodiesterase inhibitors (e.g., sildenafil), dopamine receptor agonists (e.g., apomorphine), cytotoxic antibodies (e.g., T-cell receptor and IL-2 receptor-specific antibodies), B cell depleting therapies (e.g., anti-CD20 antibody (e.g., rituxan), i-BLyS antibody), drugs affecting T cell migration (e.g., anti-integrin alpha 4 / beta 1 antibody (e.g., tysabri), drugs that act on immunophilins (e.g., cyclosporine, tacrolimus, sirolimus, rapamicin), interferons (e.g., IFN-|3), immunomodulators (e.g., glatiramer), TNF-binding proteins (e.g., circulating receptors), immunosupressants (e.g., mycophenolate), and metaglidasen, AMG-131, balaglitazone, MBX-2044, rivoglitazone, aleglitazar. chiglitazar, lobeglitazone, PLX-204, PN-2034, GFT-505, THR-0921. exenatide, exendin-4, memantine, midazolam, ketoconazole, ethyl icosapentate, clonidine, azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, etoposide, piroxicam. NO donating agents (e.g., organonitrates), and NO promoting agents (e.g., phosphodiesterase inhibitors).
[0201] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-emetic agents. As used herein, an “anti-emetic” agent refers to any agent that counteracts (e.g., reduces or removes) nausea or emesis (vomiting). It is to be understood that when referring to a therapeutically effective amount of an anti-emetic agent, the amount administered is an amount needed to counteract (e.g., reduce or remove) nausea or emesis (vomiting). While not wishing to be bound by theory, it is believed that administering one or more anti-emetic agents in combination with the formula (I) compounds described herein may allow higher dosages of the formula (I) compounds to be administered, e.g., because the patient may be able to have a normal food intake and thereby respond faster to the treatment.
[0202] Non-limiting examples of anti-emetic agents include 5HT3-receptor antagonists (serotonin receptor antagonists), neuroleptics / anti-psychotics, antihistamines, anticholinergic agents, steroids (e.g., corticosteroids), NK1 -receptor antagonists (e.g.. Neurokinin 1 substance P receptor antagonists), antidopaminergic agents / dopamine receptor antagonists, benzodiazepines, cannabinoids.
[0203] For example, the antiemetic agent can be selected from the group consisting of; neuroleptics, antihistamines, anti-cholinergic agents, steroids, 5HT-3-receptor antagonists, NK1 -receptor antagonists, anti- dopaminergic agents / dopamine receptor antagonists, benzodiazepines and non- psychoactive cannabinoids.
[0204] In some embodiments, the anti-emetic agent is a 5HT3-receptor antagonist (serotonin receptor antagonist). Non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: Granisetron (Kytril), Dolasetron, Ondansetron (Zofran), Tropisetron, Ramosetron, Palonosetron, Alosetron, azasetron, Bemesetron, Zatisetron, Batanopirde, MDL-73147EF;Metoclopramide, N-3389 (endo-3,9-dimethyl-3,9-diazabicyclo[3,3,l]non-7-yl-l H- indazole-3-carboxamide dihydrochloride), Y-25130 hydrochloride, MDL 72222, Tropanyl-3,5-dimethylbenzoate, 3-(4-Allylpiperazin-l-yl)-2-quinoxalinecarbonitrile maleate, Zacopride hydrochloride, and Mirtazepine. Other non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: cilansetron, clozapine, cyproheptadine, dazopride, hydroxyzine, lerisetron, metoclopramide, mianserin, olanzapine, palonosetron (+ netupitant), quetiapine, qamosetron, ramosteron, ricasetron, risperidone, ziprasidone, and zatosetron.
[0205] In certain embodiments, the 5HT-3-receptor antagonist is Granisetron, Dolasetron, Ondansetron hydrochloride, Tropisetron, Ramosetron, Palonosetron, Alosetron, Bemesetron, Zatisetron, Batanopirde, MDL-73147EF, Metoclopramide, N-3389, Y- 25130 hydrochloride, MDL 72222, Tropanyl-3,5-dimethylbenzoate 3-(4-Allyl piperazin-1-yl)-2-quinoxalinecarbonitrile maleate, Zacopride hydrochloride and Mirtazepine.
[0206] In certain embodiments, the 5HT-3-receptor antagonist is Granisetron, Dolasetron, Ondansetron hydrochloride, Tropisetron, Ramosetron, Palonosetron, Alosetron, Bemesetron, and Zatisetron.
[0207] In certain embodiments, the 5HT-3-receptor antagonist is Granisetron. Dolasetron and Ondansetron.
[0208] In certain embodiments, the 5HT-3-receptor antagonist is Granisetron.
[0209] In certain embodiments, the 5HT-3-receptor antagonist is Ondansetron.
[0210] In some embodiments, the anti-emetic agent is an antihistamine. Non-limiting examples of antihistamines include: piperazine derivatives (e.g., cyclizine, meclizine, and cinnarizine); Promethazine; Dimenhydrinate (Dramamine, Gravol); Diphenhydramine; Hydroxyzine; Buclizine; and Meclizine hydrochloride (Bonine, Antivert), doxylamine, and mirtazapine.
[0211] In some embodiments, the anti-emetic agent is an anticholinergic agent (Inhibitors of the acetylcholine receptors). Non-limiting examples of anticholinergic agents include: atropine.Scopolamine, Glycopyrron, Hyoscine, Artane (Trihexy-5 trihexyphenidyl hydrochloride), Cogentin (benztropine mesylate), Akineton (biperiden hydrochloride), Disipal (Norflex orphenadrine citrate), diphenhydramine, hydroxyzine, hyoscyamine, and Kemadrin (procyclidine hydrochloride).
[0212] In some embodiments, tire anti-emetic agent is a steroid (e.g., a corticosteroid). Non-limiting examples of steroids include: betamethasone, Dexamethasone, Medrylprednisolone, Prednisone®, and Trimethobenzamide (Tigan).
[0213] In some embodiments, the anti-emetic agent is an NK1 -receptor antagonists (e.g., Neurokinin 1 substance P receptor antagonists). Non-limiting examples of NK1 -receptor antagonists include: aprepitant, casopitant. ezlopitant, fosaprepitant, maropitant, netupitant, rolapitant, and vestipitant.
[0214] Other non-limiting examples of NK1 -receptor antagonists include: MPC-4505, GW597599, MPC-4505, GR205171, L-759274, SR 140333, CP-96,345, BIIF 1149, NKP 608C, NKP 608A, CGP60829, SR 140333 (Nolpitantiumbesilate / chloride), LY 303870 (Lanepitant), MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, YM- 49244, YM-44778, ZM-274773, MEN-10930, S-19752, Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK- 33A, 6b-l, CJ-11974 j. Benserazide and carbidopa k. TAK-637 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,1 l-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[l,4]diazocino[2,l-g] [1,7]naphthyridine-6.13-dione], PD 154075, ([(2-benzofuran)-CH2OCO]-(R)-alpha-MeTrp-(S)- NHCH(CH3)Ph), FK888. and (D-Pro4, D- Trp7,9,10, Phell)SP4-ll.
[0215] In some embodiments, the anti-emetic agent is a non-psychoactive cannabinoids (e.g., Cannabidiol (CBD), Cannabidiol dimethylheptyl (CBD-DMH), Tetra-hydro-cannabinol (THC), Cannabinoid agonists such as WIN 55-212 (a CB1 and CB2 receptor agonist), Dronabinol (Marinol®), and Nabilone (Cesamet)).
[0216] Other exemplary anti-emetic agents include: c-9280 (Merck); benzodiazepines (diazepam, midazolam, lorazepam); neuroleptics / anti-psychotics (e.g., dixyrazine, haloperidol, and Prochlorperazine (Compazine®)); cerium oxalate; propofol; sodium citrate; dextrose; fructose(Nauzene); orthophosphoric acid; fructose; glucose (Emetrol); bismuth subsalicylate (Pepto Bismol); ephedrine; vitamin B6; peppermint, lavender, and lemon essential oils; and ginger.
[0217] Still other exemplary anti-emetic agents include those disclosed in US 20120101089A1; US 10,071,088 B2; US 6,673,792 Bl; US 6,197,329 Bl; US 10,828,297 B2; US 10,322,106 B2; US 10,525,033 B2; WO 2009080351 Al; WO 2019203753 A2; WO 2002020001 A2; US 8,119,697 B2; US 5,039,528; US20090305964A1; and WO 2006 / 111169, each of which is incorporated by reference in its entirety.
[0218] In some embodiments, the additional therapeutic agent or regimen is administered to the patient prior to contacting with or administering the compounds and pharmaceutical compositions (e.g., about one hour prior, or about 6 hours prior, or about 12 hours prior, or about 24 hours prior, or about 48 hours prior, or about 1 week prior, or about 1 month prior).
[0219] In some embodiments, the additional therapeutic agent or regimen is administered to the patient at about the same time as contacting with or administering the compounds and pharmaceutical compositions. By way of example, the additional therapeutic agent or regimen and the compounds and pharmaceutical compositions are provided to the patient simultaneously in the same dosage form. As another example, the additional therapeutic agent or regimen and the compounds and pharmaceutical compositions are provided to the patient concurrently in separate dosage forms.EXAMPLES
[0220] This disclosure is further understood by reference to the following examples, which are intended to be purely exemplary of the disclosure. The present disclosure is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the disclosure only.GSBR-0047-WQAny methods that are functionally equivalent are within the scope of the disclosure. Various modifications of the disclosure in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.
[0221] Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons (DA) in the substantia nigra (SN). Exendin-4, a GLP-1 receptor (GLP-1R) agonist peptide, has shown beneficial effects in preclinical PD models; however the effects of small molecule GLP-1 R agonists in preclinical PD-like models remain unclear. This study aimed to evaluate the neuroprotective potential of an oral small molecule GLP-1 R agonist in a preclinical PD model.
[0222] In order to investigate the potential protective in vivo effect of GLP-1 R agonist, Compound 12, on Parkinson’s disease, a MPTP-induced PD-like model in humanized GLP-1R (hGLP-lR) mice (23-week-old males) was established. This model was generated using CRISPR gene-editing technology to express the human GLP-1 receptor instead of tire murine receptor. Compound 12 in parallel with exendin-4 and Semaglutide, both of which are the GLP-1R agonist peptides, were tested.Dosing and Treatment
[0223] Mice were pretreated with exendin-4, semaglutide, and a small molecule GLP-1 R agonist at low initial doses, which were escalated every two days. After 7-days acclimation, pre-dosing was conducted for all groups. Lower initial doses were administered for exendin-4 (1.2 nmol / kg, s.c., QD). semaglutide (2 nmol / kg, s.c., QD), and Compound 12 (0.375 mg / kg. p.o., QD), with doses gradually increased every two days. Following a 6-days titration phase, the final doses were maintained until the end of the study. The study design details are presented in the scheme shown in FIG. 1.MPTP Administration
[0224] After 8 days of pre-dosing, all animals (except normal control group) received intraperitoneal (i.p.) injections of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP, 30 mg / kg, QD) in normal saline for 7 consecutive days (FIG. 1).Behavioral Assessments
[0225] In animal models of Parkinson’s disease (PD), behavioral tests are critical for evaluating motor impairments associated with dopaminergic neurodegeneration. Three commonly used assessments are the pole test, rotarod test, and open field test, each targeting distinct aspects of motor function and activity.1. Pole test
[0226] The pole test was conducted on day -4, 0, 2, 4. As shown in FIG.2, the climbing duration of MPTP model group showed significant increase compared to the normal group. Exendin-4 couldeffectively decrease tire climbing duration 7 days post of MPTP-induction in hGLP-1R mice. Compound 12 also decreases tire climbing duration.2. Rotarod test
[0227] The rotarod test was conducted on day -4, 1, 2. 5. 6. As shown in FIG.3, tire latency to fall of MPTP model group showed significant decrease compared to the normal group. All treatments could effectively increase the latency 7 days post MPTP-induction in hGLP-1R mice.3. Open field test
[0228] The open field test was conducted on Day 7 after the first MPTP injection. As shown in FIG. 4A-4E, all the parameters (distance traveled, speed, central zone distance, and central zone entrance) of the open field test revealed the MPTP model showed significant decrease compared to the normal group. All treatments could effectively increase tire total distance (FIG.4B) and average speed (FIG. 4C) post 7 days MPTP-induction in hGLP-1R mice. Compound 12 also significantly improved the entrance to central zone (FIG. 4E).Histopathology
[0229] All animals were euthanized on Day 8, and whole brains were collected and fixed in 10% formalin. Tyrosine hydroxylase (TH) expression in the substantia nigra (SN) was analyzed using immunohistochemistry (IHC) staining to quantify the dopamine neurons.
[0230] As shown in FIG. 5A-5B. the MPTP model group showed significant decrease on DA neurons. The 3 mpk Compound 12 and 12 nmol / kg exendin-4 show significantly increased tire dopamine neurons after MPTP-induction in PD-like mice.
[0231] In conclusion, Compound 12 showed beneficial effects on tire motor deficits and neuron loss in MPTP induced PD-like mice. Particularly, Compound 12 could improve tire recovery on the autonomous activity or motor deficits in the tests of pole, rotarod and open field. In open field test and histology assessment of DA neuron protection, tire effects of 3 mpk Compound 12 were comparable to 12 nmol / kg Exendin-4.Weight loss effect
[0232] The body weight was measured daily. As shown in FIG. 6A-6C, Compound 12 exhibited a clear effect on body weight loss, while the body weight of the Normal control group remained relatively stable. On Day 3 post MPTP-induction, the maximum body weight loss was 18.13%, which is higher than the exendin-4 group (9.52%) and Semaglutide (14.28%).Reduced Food intake
[0233] Throughout tire experiment, the normal control group maintained a relatively stable food intake. After MPTP administration, all groups exhibited a significant reduction in food intake, followed by agradual recovery. Notably, the Compound 12 3 mpk group continued to demonstrate a significant appetite-suppressing effect on Day 5 compared to the MPTP model group (FIG.6D-6E).
[0234] These findings suggest this oral small molecule GLP-1R agonist showed neuroprotective effects by mitigating motor deficits and preserving DA neuron in MPTP-induced PD model. This highlights a potential benefit in Parkinson’s disease.
Claims
CLAIMS1. A method for treating or preventing Parkinson’s Disease (PD) in a subject, comprising orally administrating an effective amount of glucagon-like peptide- 1 (GLP-1) receptor agonist to the subject, wherein the GLP-1 receptor agonist is selected from a compound of Formula I:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof, wherein:Q2is N or CRQA;RQBis -S(O)(NRa)Rbor -P(O)Ra’Rb’;Rais hydrogen, cyano, Ci-g alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of halo, oxo, Ci-e alkoxy, C3-6 cycloalkyl, and heteroaryl, C3-6 cycloalkyl optionally substituted with 1 -3 substituents each independently selected from the group consisting of C1-3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1.3 alkyl;Rbis Ci-6 alkyl which is optionally substituted with 1-6 substituents each independently selected from the group consisting of C1.6 alkoxy, C3-6 cycloalkyl, and halo, C3-6 cycloalkyl optionally substituted with 1 -3 substituents each independently selected from the group consisting of C1.3 alkyl and halo, or Ce-io aryl optionally substituted with 1-3 independently selected C1-3 alkyl;or Raand Rbtaken together with the atoms to which each is attached form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-3 independently selected Ci-e alkyl;Ra’ and Rb’ are independently selected from the group consisting of C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of Ci-e alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and Ce-io aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; orRa’ and Rb’ taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra’ and Rb’) are heteroatoms each independently selected from the group consisting of: 0, S, and N. wherein the ring is optionally substituted with from 1-3 independently selected C1-6 alkyl:each RQA is independently hydrogen, halo, cyano, hydroxy, -NRcRd, -C(O)NRcRd, -S(O)0-2Re, C1-6 alkyl optionally substituted with 1-6 independently selected Rf, C1-6 alkoxy optionally substituted with 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy, 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and -C(O)(C1-6 alkyl), C6-10 aryl optionally substituted with 1-3 independently selected -C(O)(C1-6 alkyl), and 5-10 membered heteroaryl optionally substituted with 1-6 independently selected Rg;or Raor Rband an adjacent RQAare taken together with the atom to which each is attached to form a 5-8 membered heterocyclyl, wherein said heterocyclyl is optionally substituted with 1-2 independently selected Rh;q is O, 1, 2, 3, 4, or 5;each RA is independently halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or C3-6 cycloalkyl;R3 is hydrogen or C1-6 alkyl optionally substituted with 1-6 substituents independently selected from the group consisting of halo, hydroxy, and C1-6 alkoxy;R9is -C(O)OR9a, -C(O)NR9aR9b, 5-6 membered heteroaryl optionally substituted with 1 -3 independently selected R9c, 4-6 membered heterocyclyl optionally substituted with 1-3 independentlyX1is O or S;R9ais hydrogen or Ci-6 alkyl;R9bis hydrogen, Ci-e alkyl, -C(O)(Ci-6 alkyl), -S(0)o-2(Ci-6 alkyl), or cyano;each R9c is independently hydrogen, oxo, C1-6 alkyl optionally substituted with 1-6 independently selected halo and C1-6 alkoxy, or -C(O)(C1-6 alkyl);v is 0, 1, 2, or 3;each RCa is independently halo, cyano, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, or NRcRd; or a pair of RCaon the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including 3-8 ring atoms;each Rc and Rd are each independently hydrogen, C1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(C3-6 cycloalkyl), -C(O)O(C1-6 alkyl), -S(O)1-2(C1-6 alkyl), or -S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, -C(O)(C1-6 alkyl), -C(O)(C3-6 cycloalkyl), -C(O)O(C1-6 alkyl), -S(O)1-2(C1-6 alkyl), and -S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with 1-6 substituents independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy;each Re is independently hydrogen, C1-6 alkyl, or C1-6 haloalkyl;w is 0, 1, 2, or 3;each R1f is independently C1-6 alkyl, wherein each C1-6 alkyl is independently optionally substituted with 1-6 independently selected Rf;each Rf is independently halo, hydroxy, -NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, or 3-12 membered heterocyclyl which is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxy, C1-6 alkyl, and 3-12 membered heterocyclyl;each Rg is independently C1-6 alkyl, C1-6 alkoxy, -NRcRd, or 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and -C(O)C1-6 alkyl; andeach R11is independently halo, cyano, hydroxy, Ci-g alkyl, Ci.g haloalkyl, -NH2, -NH(CI-3 alkyl), -N(CI-3alkyl)2, C1-3 alkoxy, or C1-3 haloalkoxy.
2. The method of claim 1, wherein RQBis -S(O)(NRa)Rb3. The method of claim 1, wherein the GLP-1 receptor agonist is a compound of Formula II:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
4. The method of any preceding claim, wherein Rais hydrogen or Ci-g alkyl.
5. The method of any preceding claim, wherein Rbis Ci.g alkyl or C3-6 cycloalkyl.
6. The method of any preceding claim, wherein Rais hydrogen, methyl, or etiiyl; and Rbis methyl, ethyl, cyclopropyl, or cyclobutyl.
7. The method of any preceding claim, wherein Q2is CH.
8. The method of any preceding claim, wherein each RQAis independently hydrogen, halo,-NHCH3, or methyl.
9. The method of any preceding claim, wherein RQBis -P(O)Ra’Rb’.
10. The method of claim 1, wherein the GLP-1 receptor agonist is a compound of Formula III:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
11. The method of claim 1 or 10, wherein Ra’ and Rb’ are each independently methyl, ethyl, or cyclopropyl.
12. The method of claim 1 or 10, wherein Ra’ and Rb’ are each independently C1.3 alkyl.
13. The method of claim 1 or 10, wherein Ra’ and Rb’ are each ethyl.
14. The compound of any preceding claim, wherein R3is methyl.
15. The method of claim 1, wherein the GLP-1 receptor agonist is a compound selected from Table 1 or 2, or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
16. The method of claim 1, wherein the GLP-1 receptor agonist is Compound 12:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
17. The method of claim 1, wherein the GLP-1 receptor agonist is Compound 17:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
16. The method of claim 1, wherein the GLP-1 receptor agonist is Compound 18:or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, prodrug, or solvate thereof.
17. The method of any preceding claim, wherein the GLP-1 receptor agonist is administered to the subject daily, every other day, every two days, every three days, once per week, twice per week, once every two weeks, or once monthly.
18. The method of any preceding claim, further comprising administering an additional therapy.
